Widthness LLC

Advanced Business and Technology – Intel® Xeon® and A.I. Powered

Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

1 min read
Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials

Image caption: A unique once-a-day pill to treat ALS has been approved for ongoing clinical trials. Image credit: Depositphotos. Article by Paul McClure. New Atlas – May 29, 2024. Source: Spinogenix.

Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, affects nerve cells in the brain and spinal cord, called motor neurons, that control voluntary muscle movements like walking, talking, and breathing. As the neurons die and can’t send messages to the muscles, loss of muscle control worsens over time and is eventually fatal. […]

The owner of this website has made a commitment to accessibility and inclusion, please report any problems that you encounter using the contact form on this website. This site uses the WP ADA Compliance Check plugin to enhance accessibility.